UCB-guided surrogate Bayesian optimization (validated for drug discovery) will outperform EI in identifying MSH3-selective inhibitors when augmented with rewrite-acceptability verification (Theoria framework) to filter sycophantic LLM-generated binding hypotheses, reducing biochemical assay false positives by ≥50%.
UCB-guided surrogate Bayesian optimization (validated for drug discovery) will outperform EI in identifying MSH3-selective inhibitors when augmented with rewrite-acceptability verification (Theoria framework) to filter sycophantic LLM-generated binding hypotheses, reducing biochemical assay false positives by ≥50%.
Adversarial Debate Score
66% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- Budget-Sensitive Discovery Scoring: A Formally Verified Framework for Evaluating AI-Guided Scientific Selection
Scientific discovery increasingly relies on AI systems to select candidates for expensive experimental validation, yet no principled, budget-aware evaluation framework exists for comparing selection s...
- Trustworthy Protein-Ligand Binding Affinity Prediction via Reliability-Aware Multi-Engine Fusion
Accurate protein-ligand binding affinity prediction is central to computational drug discovery, yet modern docking engines frequently disagree without indicating which prediction to trust. Consensus s...
- Empowering Chemical Structures with Biological Insights for Scalable Phenotypic Virtual Screening
Motivation: The scalable identification of bioactive compounds is essential for contemporary drug discovery. This process faces a key trade-off: structural screening offers scalability but lacks biolo...
- TxBench-PP: Analyzing AI Agent Performance on Small-Molecule Preclinical Pharmacology
Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic prog...
- DBMol: Design of High-Affinity, Target-Specific Small Molecules through Structure Prediction Models
Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeuti...
Computational Result
An LLM's reading of the literature — not computational verification.
Evidence supports Bayesian optimization but lacks consensus on filtering efficacy.
Method: literature_meta · Result: inconclusive · Confidence: 65%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
Given a fixed compound library (virtual + purchasable) and a fixed surrogate model architecture (Gaussian Process or Bayesian neural network) trained on MSH3-selectivity-relevant biochemical/biophysical descriptors, an active learning loop that (a) selects next candidates via Upper Confidence Bound (UCB) acquisition and (b) filters LLM-generated binding-mode hypotheses through a "rewrite-acceptability verifier" (Theoria-style consistency/sycophancy check before those hypotheses are allowed to inform surrogate priors or candidate ranking) will, over N=200–500 total assayed compounds and ≥3 independent optimization runs, achieve (i) a hit-identification rate for confirmed MSH3-selective inhibitors (selectivity ratio vs. MSH2/MSH6 paralogs ≥5x, IC50 ≤10 µM) that is statistically non-inferior to or better than an Expected Improvement (EI)-guided loop without the verifier, AND (ii) a ≥50% relative reduction in biochemical assay false-positive rate (compounds flagged as promising by the pipeline but failing dose-response/selectivity confirmation) compared to an EI+unfiltered-LLM-hypothesis baseline, at p<0.05 (paired permutation test across matched optimization runs/seeds).
- UCB+Theoria fails to show statistically significant improvement (p≥0.05) in hit rate over EI+Theoria across ≥3 seeds/runs — disproves the UCB-superiority sub-claim.
- False-positive reduction is <50% relative, or is not statistically distinguishable from a matched ablation using EI+Theoria (i.e., the gain is attributable to Theoria alone, not the UCB/EI choice) — disproves the combined claim as stated.
- Theoria filtering removes >30% of eventually-confirmed true positives (precision-recall tradeoff unacceptable), indicating the verifier is over-aggressive rather than selectively removing sycophantic hallucinations.
- No measurable difference between UCB and EI when Theoria is absent (both baselines perform equivalently), suggesting the entire effect is driven by verification, not acquisition function choice — this would require reframing the hypothesis as "verification matters, acquisition function choice does not."
- Results fail to replicate in an independent MSH3 assay batch (different lab/reagent lot) at same effect size ± 15%.
Spine & Adversarial Read
- highThe design conflates two independent variables (acquisition function choice and verification presence) into a single combined claim, making it unclear whether any observed effect is attributable to UCB, to Theoria, or to their interaction — the 2x2 factorial helps but the headline hypothesis as stated bundles them.The 2x2 factorial design in the protocol does decompose this (UCB±Theoria, EI±Theoria), and disproof criteria explicitly include the case where Theoria alone drives the effect. However, the EVP does not yet specify a pre-registered analysis plan for interaction effects (ANOVA-style decomposition) — this should be added before execution to avoid post-hoc reinterpretation.
- highNo justification is given for why GP/BNN surrogate + UCB/EI specifically (rather than e.g. Thompson sampling, or non-Bayesian active learning baselines like uncertainty sampling or diversity-based selection) was chosen as the comparison set, nor why Theoria specifically over other hallucination-detection methods (e.g., self-consistency checks, retrieval-grounding).This is an acknowledged gap. The choice of UCB/EI is justified by their status as the two most common, well-theorized acquisition functions in BO-for-drug-discovery literature, giving external comparability, but no ablation against Thompson sampling or non-BO baselines is included in this protocol — this narrows the claim's generalizability and should be flagged explicitly in any publication as a scope limitation, or added as a third arm if budget allows.
- mediumThe proposed budget (200-500 assayed compounds, 3 seeds) may be statistically underpowered to detect a 50% relative reduction in false-positive rate with the required confidence, especially given typical hit rates in biochemical screens (often 1-5%), which would leave very few actual positive/negative-confirmed compounds per arm to compute a stable false-positive rate.This is a real risk not fully resolved in the current design. A power analysis based on assumed baseline hit rate and false-positive rate variance should be run before finalizing N; the EVP's full-validation budget (1,500-2,000 compounds) partially addresses this but the MVP tier (200-600) may only be sufficient for a preliminary directional signal, not a definitive statistical claim — this should be stated as a limitation of the MVP tier specifically.
Experimental Protocol
Minimum viable test: 2×2 factorial design — {UCB, EI} × {Theoria-filtered, unfiltered LLM hypotheses} — run as 4 parallel active-learning loops over a shared candidate pool, each loop selecting 10 compounds per round for 5 rounds (50 compounds/loop, 200 total assay points minimum), replicated across 3 random seeds (600 assay points total for MVP; full validation scales to 1,500–2,000 assay points across 2 chemical libraries).
- MSH3 biochemical/biophysical assay dataset: purified MSH3-MSH2 (MutSβ) ATPase/mismatch-binding assay, counter-screened against MSH2-MSH6 (MutSα); target n≥1,500 compounds tested experimentally over the study.
- Public DNA mismatch repair inhibitor datasets (ChEMBL target CHEMBL... MSH2/MSH3/MSH6 bioactivity records) for surrogate model pretraining/prior.
- Virtual screening library: minimum 50,000-compound diverse subset (e.g., Enamine HTS collection or ZINC20 drug-like subset) with precomputed descriptors/fingerprints (ECFP4, physicochemical properties).
- Theoria rewrite-acceptability verifier: requires a labeled sycophancy/consistency benchmark for biochemical claim rewrites (must be constructed if not existing — est. 500–1,000 labeled LLM output pairs, human-annotated for hallucination/sycophancy).
- LLM binding-hypothesis generator: GPT-4-class or open-weight equivalent (e.g., Llama-3-70B) fine-tuned or prompted for structure-activity rationale generation.
- Surrogate BO framework: GPyTorch/BoTorch or Ax platform for GP/BNN + UCB/EI implementation.
- Primary: ≥50% relative reduction in false-positive rate for UCB+Theoria vs EI+unfiltered baseline, 95% CI excluding 50% lower bound, p<0.05.
- Secondary: UCB+Theoria hit rate ≥ EI+Theoria hit rate (non-inferiority margin 5 percentage points) across ≥3 seeds.
- Theoria filter precision: removes ≥60% of hallucinated/sycophantic hypotheses (validated against human-annotated holdout) while retaining ≥85% of hypotheses later confirmed correct.
- Surrogate model calibration: ECE <0.10 maintained throughout active learning rounds.
- Orthogonal assay confirmation rate for top hits ≥70%.
- False-positive reduction <25% relative or not statistically significant (p≥0.05).
- UCB+Theoria hit rate more than 5 percentage points below EI+Theoria (indicating UCB is actually inferior in this regime).
- Theoria filter shows no significant difference in precision/recall vs random filtering (verifier adds no signal).
- Results fail to replicate within ±15% effect size in independent batch/lab.
- Surrogate calibration degrades (ECE >0.20) during active learning, invalidating UCB's theoretical justification.
ROI Projection
Direct value to biotech/pharma running AI-augmented hit-to-lead pipelines (estimated addressable segment: mismatch-repair-targeted oncology programs, synthetic lethality programs exploiting MSH3 instability in MSI-high cancers — a growing niche given recent MSH3/microsatellite instability oncology interest). Broader commercial value as a generalizable "LLM hypothesis verification layer" for computational drug discovery SaaS platforms; could be licensed/integrated into existing BO-for-drug-discovery platforms (e.g., Ax/BoTorch-based commercial offerings). Estimated market relevance: modest-to-moderate (niche target, but methodology generalizes broadly).
TIME_TO_RESULT_DAYS: 270
Implementation Sketch
# Pseudocode: 2x2 factorial active learning loop for acquisition in [UCB, EI]: for verification in [Theoria_ON, Theoria_OFF]: for seed in [1,2,3]: surrogate = GP_or_BNN(pretrain_data=ChEMBL_MSH_data, seed=seed) pool = load_library(n=50000) selected_hits = [] for round in range(5): candidates = acquisition_function(surrogate, pool, batch_size=10) if verification == Theoria_ON: llm_hypotheses = generate_binding_rationale(candidates, LLM) filtered = theoria_verify(llm_hypotheses, threshold=tuned_thresh) candidates = rerank_or_filter(candidates, filtered) assay_results = run_biochemical_assay(candidates) # wet lab surrogate.update(candidates, assay_results) pool.remove(candidates) selected_hits.extend(assay_results) log_metrics(acquisition, verification, seed, selected_hits) # Post-hoc analysis compute_hit_rate(), compute_false_positive_rate(), permutation_test(UCB_Theoria, EI_Theoria)
- After Round 2 (Day ~90): if Theoria verifier precision/recall on holdout is not significantly better than random (check before committing further assay budget).
- After Round 3 (Day ~150): if no separation between UCB and EI hit rates is emerging (interim analysis, not final) and confidence intervals are wide and overlapping — consider reallocating budget to increase N per condition rather than continuing as planned.
- Mid-study surrogate calibration check (Day ~120): if ECE >0.20, halt and recalibrate before further rounds, since UCB validity depends on calibration.
- After orthogonal assay validation of first batch of hits (Day ~200): if confirmation rate <40%, primary assay may be unreliable — halt and revalidate assay protocol before continuing.
NAMED_EXPERTS: []
CLOSEST_EXISTING_WORK: []
NOVELTY_NARROWING_REQUIRED: false
SPINE_STATEMENT: This hypothesis tests whether adding a rewrite-acceptability (sycophancy-filtering) verification layer to a UCB-guided Bayesian optimization loop reduces MSH3-selective-inhibitor assay false positives by at least 50% relative to an EI-guided loop without such verification.